Form 4: Brainstorm Cell Therapeutics CEO Lebovits Increases Stake in Company

Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired additional shares of the company's common stock through multiple transactions.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, has reported changes in his beneficial ownership of the company's stock.
• On September 30, 2024, Lebovits purchased 22,000 shares of common stock at a weighted average price of $0.228 per share.
• On October 1, 2024, following a 1-for-15 reverse stock split, Lebovits purchased an additional 1,836 shares at a weighted average price of $3.4272 per share.
• Following these transactions, Lebovits directly owns 80,960 shares and indirectly owns 133,389 shares.
• The indirect ownership includes shares held by ACCBT Corp. (128,919 shares) and ACC International Holdings Ltd. (4,470 shares).

Sentiment

Score: 6

Explanation: The CEO's stock purchases are a mildly positive signal, suggesting confidence. However, the reverse stock split is often viewed negatively as it can indicate financial distress or an attempt to artificially inflate the stock price.

Positives

• The CEO's purchase of additional shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the CEO's stock purchases as a positive sign, potentially increasing investor confidence.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, Stock, Beneficial Ownership, SEC Form 4, Reverse Stock Split